4.8 Article

Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach

Journal

CELL
Volume 125, Issue 7, Pages 1253-1267

Publisher

CELL PRESS
DOI: 10.1016/j.cell.2006.05.030

Keywords

-

Funding

  1. Howard Hughes Medical Institute Funding Source: Medline
  2. NCI NIH HHS [P30 CA008748, R01 CA078544, CA078544, CA87497, CA13106, P01 CA013106, U01 CA105388, CA105388, P01 CA087497] Funding Source: Medline

Ask authors/readers for more resources

The heterogeneity and instability of human tumors hamper straightforward identification of cancer-causing mutations through genomic approaches alone. Herein we describe a mouse model of liver cancer initiated from progenitor cells harboring defined cancer-predisposing lesions. Genome-wide analyses of tumors in this mouse model and in human hepatocellular carcinomas revealed a recurrent amplification at mouse chromosome 9qA1, the syntenic region of human chromosome 11q22. Gene-expression analyses delineated cIAP1, a known inhibitor of apoptosis, and Yap, a transcription factor, as candidate oncogenes in the amplicon. In the genetic context of their amplification, both cIAP1 and Yap accelerated tumorigenesis and were required to sustain rapid growth of amplicon-containing tumors. Furthermore, cIAP1 and Yap cooperated to promote tumorigenesis. Our results establish a tractable model of liver cancer, identify two oncogenes that cooperate by virtue of their coamplification in the same genomic locus, and suggest an efficient strategy for the annotation of human cancer genes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available